JSR Corporation announced today that it has concluded a facility use agreement with KINS Co., Ltd. (KINS), a company with a database of human microbiome.
Crown Bioscience and MBL announce the formation of a joint venture, to further expand the provision of Crown Bioscience’s preclinical services to Japanese customers.
Selexis SA announced today that Great Place to Work® has designated the Company among the “Best Workplaces Switzerland™” in 2022. This is the fifth straight year Selexis has earned this recognition.
Crown Bioscience, a JSR Life Sciences company, and HUB Organoids (HUB) announced today the publication of preclinical data in the journal, Nature Cancer, on a bispecific antibody which prevents the...
KBI, a JSR Life Sciences company, held a ribbon-cutting at the company’s new state-of-the-art $150 million, 150,000 square-foot commercial manufacturing facility in Research Triangle Park (RTP), No...
JSR Life Sciences, LLC is pleased to announce that JSR Corporation and Asahi Kasei Medical have entered into a co-promotion agreement for bioprocess products and materials that initiated sales coll...
Anti-integrin αvβ6 antibodies are detected in about 90% of UC patients, and the results of basic research suggest that these autoantibodies themselves may be causing the disease
JSR Life Sciences announced that its lead product, Amsphere™ A3 has been incorporated for the first time into the commercial manufacturing of an FDA-approved treatment
This project will conduct R&D aimed at the establishment and practical application of a wide range of fundamental technologies related to intestinal microbiome drug discovery for the creation of in...
MBL donated 20,000 their SARS-CoV-2 antigen test kits "GLINE-2019-nCoV Ag kit" to Ina City, Nagano Prefecture, where their research and production facilities are located
6 of 23
Receive JSR Life Sciences news on your RSS reader.
